The cardiovascular longevity metrics your annual physical does not include

What the annual physical misses

Cardiovascular disease remains the leading cause of death in midlife adults. The standard lipid panel ordered at most annual physicals was designed in the 1970s based on the technology available at the time and the understanding of cardiovascular risk that existed then. Both the technology and the understanding have advanced substantially. The panel has not.

A person can have a normal LDL, normal blood pressure, and a normal fasting glucose while having an ApoB of 140, an Lp(a) of 80, and a coronary artery calcium score of 200 that together indicate high cardiovascular risk that will not appear in the standard panel. Conversely, a person can have a borderline-elevated LDL and a CAC of zero, suggesting very low near-term coronary artery disease risk despite the LDL number. The standard panel cannot distinguish these situations. The expanded markers can.

The four markers worth knowing

ApoB (apolipoprotein B). Every atherogenic lipoprotein particle (LDL, VLDL, IDL, Lp(a)) carries exactly one ApoB molecule. ApoB directly counts the number of atherogenic particles rather than estimating their cholesterol content. In large cohort studies, ApoB predicts cardiovascular events more accurately than LDL cholesterol, particularly in people with elevated triglycerides or insulin resistance where LDL particle number and LDL cholesterol diverge. Target below 80 mg/dL for low risk; below 60 mg/dL is optimal for longevity-focused adults.

Lp(a) (lipoprotein-a). An LDL-like particle with an additional apo(a) protein attached. Lp(a) is proatherogenic, prothrombotic, and largely unresponsive to lifestyle or standard lipid medications. Approximately 20 percent of the population has an Lp(a) above 50 mg/dL, which confers a two- to threefold increased cardiovascular risk independent of LDL. Test it once; it does not change significantly over time. New RNA-based medications specifically targeting Lp(a) are in late-stage trials and approaching approval, making baseline knowledge increasingly actionable.

Coronary artery calcium (CAC) score. A non-contrast CT scan of the heart that quantifies calcified plaque in the coronary arteries. A CAC of zero in an adult over 50 confers very low cardiovascular event risk over the subsequent 10 years, independent of traditional risk factors. A CAC above 100 indicates established subclinical coronary artery disease requiring more aggressive risk factor management. The MESA study of 6,814 adults showed CAC adding significant predictive value beyond all traditional risk factors combined.

Remnant cholesterol. The cholesterol carried in VLDL and IDL particles, calculated as total cholesterol minus LDL minus HDL. Elevated remnant cholesterol is causally associated with cardiovascular risk in Mendelian randomization studies and is particularly elevated in adults with metabolic syndrome, high triglycerides, or insulin resistance. Target below 30 mg/dL.

The Livium recipe

Tool. Request ApoB, Lp(a), and remnant cholesterol at the next lab visit. ApoB is widely available and often covered by insurance when ordered with standard lipids. Lp(a) requires a specific order and is not always covered; direct-pay cost is $20 to $40. A CAC scan costs $100 to $400 at most radiology centers, does not require a physician order in most states, and delivers less radiation than a mammogram.

Behavior. ApoB responds to all standard LDL-lowering interventions plus insulin-sensitizing interventions that reduce VLDL particle number. Mediterranean diet, Zone 2 exercise, TRE, and visceral fat reduction each lower ApoB. Lp(a) responds minimally to lifestyle (niacin at high doses produces modest reduction; PCSK9 inhibitors reduce it by approximately 20 to 30 percent). If Lp(a) is elevated, the appropriate response is more aggressive management of all other modifiable risk factors, not waiting for the Lp(a)-specific therapies approaching approval.

Threshold. After 12 months of cardiovascular-focused lifestyle intervention: ApoB should decline 15 to 25 percent from baseline with consistent diet and exercise improvement. Remnant cholesterol should normalize with improved insulin sensitivity. CAC rescanning is not recommended more frequently than every three to five years; it is a slow-moving marker.

Life Extension Super K with Advanced K2 Complex provides MK-4 and MK-7 forms of vitamin K2 that support routing calcium into bone rather than arterial walls, which is directly relevant to preventing coronary artery calcification. Thorne Omega-3 with CoQ10 provides high-dose EPA/DHA alongside CoQ10 for combined lipid, endothelial, and mitochondrial cardiac support. NOW Foods Nattokinase 100 mg supports fibrinolytic activity relevant to thrombotic risk reduction, particularly important in adults with elevated Lp(a), which is independently prothrombotic. Life Extension Arterial Protect combines aged garlic extract, French maritime pine bark extract, and nattokinase in a formula specifically designed for arterial wall health and endothelial function.

Source: Livium editorial synthesis based on American Heart Association Cholesterol resources and Sniderman et al., JAMA Cardiology (2019).

Plan of action

• At the next lab visit, add ApoB and Lp(a) to the standard lipid panel. Lp(a) should be tested once in every adult; it does not need repeated testing unless specifically indicated.
• Get a CAC scan if over 45 and have any cardiovascular risk factors (family history, hypertension, elevated lipids, smoking history, diabetes). A zero score provides reassurance that the disease is not yet established. A score above 100 changes the treatment urgency.
• If ApoB is above 100 and standard lipid markers look normal, understand that the ApoB number is more actionable. Discuss it specifically with a cardiologist or lipid-aware physician rather than a primary care physician who may not be familiar with the distinction.
• If Lp(a) is above 50 mg/dL, discuss this with a physician who is tracking the emerging Lp(a)-specific therapeutic pipeline. Multiple RNA medications are in Phase 3 trials and may become available within the next two to three years.